Clinical Trial Update: Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating Inupadenant (EOS100850) with chemotherapy as second-line treatment for nonsquamous non-small cell lung cancer; the study is cu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Inupadenant (inupadenant)

Snippet

Sponsor: iTeos Therapeutics | Conditions: Metastatic NSCLC - Non-Small Cell Lung Cancer, Locally Advanced NSCLC - Non-Small Cell Lung Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING